{"id":"NCT02993731","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","officialTitle":"A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2020-03","completion":"2020-03","firstPosted":"2016-12-15","resultsPosted":"2021-06-10","lastUpdate":"2023-11-15"},"enrollment":1134,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Pancreatic Ductal"],"interventions":[{"type":"DRUG","name":"Napabucasin","otherNames":["BBI-608","BBI608","BB608"]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":["Abraxane"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar"]}],"arms":[{"label":"Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine","type":"EXPERIMENTAL"},{"label":"Arm 2: Nab-paclitaxel with Gemcitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From 4 weeks after the patient has been off study therapy, every 4 weeks thereafter for 6 months, then every 3 months thereafter until death, the study closes or 3 years since treatment discontinuation.","effectByArm":[{"arm":"Napabucasin Plus Nab-paclitaxel With Gemcitabine","deltaMin":11.43,"sd":null},{"arm":"Nab-paclitaxel With Gemcitabine","deltaMin":11.73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":267,"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","France","Germany","Italy","Japan","Netherlands","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":330,"n":561},"commonTop":["Anaemia","Diarrhoea","Nausea","Alopecia","Pyrexia"]}}